Related Experiment Video

Updated: Jul 25, 2026

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
09:26

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

The potential role of platelet microparticles in atherosclerosis

Kiat T Tan1, Gregory Y H Lip

  • 1Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, England, UK.

Thrombosis and Haemostasis
|November 5, 2005
PubMed

Insights

Platelet microparticles (PMPs) released by activated platelets contribute to thrombosis and atherosclerosis. This review explores the multifaceted roles of PMPs in the progression of atherosclerosis, including inflammation and angiogenesis.

Area of Science:

  • Cardiovascular Biology
  • Hematology
  • Pathophysiology

Background:

  • Activated platelets release microvesicles, termed platelet microparticles (PMPs).
  • PMPs contain platelet membrane proteins and bioactive lipids, mediating various biological processes.
  • Evidence suggests PMPs are implicated in all stages of atherosclerosis pathobiology.

Purpose of the Study:

  • To review the literature on the role of PMPs in atherosclerosis progression.
  • To summarize the known functions of PMPs in thrombotic and inflammatory processes relevant to atherosclerosis.

Main Methods:

  • Literature review of studies investigating PMPs and atherosclerosis.
  • Synthesis of findings on PMP involvement in thrombosis, inflammation, and angiogenesis.

Main Results:

  • PMPs are integral to the thrombotic process.
  • PMPs exhibit pro-inflammatory effects, promoting atherosclerosis development.
  • Bioactive lipids within PMPs influence angiogenesis.

Conclusions:

  • PMPs play a significant role in the progression of atherosclerosis.
  • Understanding PMP functions offers insights into therapeutic strategies for atherosclerosis.

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...